Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared A Leff

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
The American Journal of Managed Care|November 20, 2018
Cost of pharmacotherapy for opioid use disorders following inpatient detoxificationKathryn E McCollister, Jared A Leff, Xuan Yang, et al.
Addiction (Abingdon, England)|October 9, 2014
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsBruce R Schackman, Jared A Leff, Devra M Barter, et al.
Public Health Reports (Washington, D.C. : 1974)|February 11, 2016
Costs of Expanded Rapid HIV Testing in Four Emergency DepartmentsBruce R Schackman, Ashley A Eggman, Jared A Leff, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|February 24, 2009
Review of complications in a series of patients with known gastro-esophageal varices undergoing transesophageal echocardiographyBret J Spier, Shane J Larue, Thomas C Teelin, et al.
Annals of Internal Medicine|December 18, 2018
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid RelapseSean M Murphy, Kathryn E McCollister, Jared A Leff, et al.
Sexually Transmitted Diseases|August 15, 2014
The cost of implementing rapid HIV testing in sexually transmitted disease clinics in the United StatesAshley A Eggman, Daniel J Feaster, Jared A Leff, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic ReviewCzarina N Behrends, Jared A Leff, Weston Lowry, et al.
Drug and Alcohol Dependence|February 26, 2018
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programsBruce R Schackman, Sarah Gutkind, Jake R Morgan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
The American Journal of Managed Care|November 20, 2018
Cost of pharmacotherapy for opioid use disorders following inpatient detoxificationKathryn E McCollister, Jared A Leff, Xuan Yang, et al.
Addiction (Abingdon, England)|October 9, 2014
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsBruce R Schackman, Jared A Leff, Devra M Barter, et al.
Public Health Reports (Washington, D.C. : 1974)|February 11, 2016
Costs of Expanded Rapid HIV Testing in Four Emergency DepartmentsBruce R Schackman, Ashley A Eggman, Jared A Leff, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|February 24, 2009
Review of complications in a series of patients with known gastro-esophageal varices undergoing transesophageal echocardiographyBret J Spier, Shane J Larue, Thomas C Teelin, et al.
Annals of Internal Medicine|December 18, 2018
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid RelapseSean M Murphy, Kathryn E McCollister, Jared A Leff, et al.
Sexually Transmitted Diseases|August 15, 2014
The cost of implementing rapid HIV testing in sexually transmitted disease clinics in the United StatesAshley A Eggman, Daniel J Feaster, Jared A Leff, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic ReviewCzarina N Behrends, Jared A Leff, Weston Lowry, et al.
Drug and Alcohol Dependence|February 26, 2018
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programsBruce R Schackman, Sarah Gutkind, Jake R Morgan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Pageof 4